Search
Innovent Achieves Over 4.7 Billion Yuan in Product Revenue for Q3, Marking a Year-on-Year Surge of Over 40%
13 hour ago /
Read about 0 minute
Author：小编
According to Innovent's financial report for the third quarter of 2026, the company's product revenue for this period soared beyond 4.7 billion yuan, signaling a robust year-on-year growth of over 40%. With a steadfast commitment to sustainable growth and global innovation, Innovent boasts a diverse and extensive product pipeline that spans across various therapeutic areas, including oncology, cardiovascular and metabolic diseases, autoimmune conditions, ophthalmology, and beyond. To date, the company has successfully obtained regulatory approvals for 20 products, encompassing 15 innovative drugs, 4 biosimilars, and 1 modified innovative drug, showcasing its prowess in pharmaceutical development and market penetration.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
